Luye Pharma Group Ltd. (Luye Pharma) reported no changes to its share capital structure for the month ended 30 September 2026, according to its latest monthly return filed with Hong Kong Exchanges and Clearing Limited on 7 October 2026.

Authorised and Issued Share Capital • Authorised share capital remained at USD 200.00 million, representing 10.00 billion ordinary shares with a par value of USD 0.02 each. • Issued share capital was unchanged at 3.99 billion ordinary shares, with no treasury shares outstanding or cancelled during the period.

Public Float Compliance Luye Pharma confirmed compliance with the Main Board’s minimum public float threshold of 25%, ensuring adequate liquidity in its shares.

Convertible Bonds Overview The company retains outstanding US$180.00 million of 5.25% convertible bonds due 2031. No conversions were executed in September, leaving the potential issuance capacity unchanged at approximately 520.50 million new shares at a conversion price of HKD 2.71 per share.

No Activity in Other Capital Instruments • No new share options, warrants, or other equity-linked instruments were granted or exercised. • There were no share repurchases, cancellations, or treasury share movements. • No Hong Kong Depositary Receipts are outstanding.

The filing, signed by Director Zhu Yuan Yuan, confirms that all regulatory and listing rule requirements have been satisfied for the reported period.